Diagnosis and Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease-Reference-Cited by-同舟云学术

Diagnosis and Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease

Published:2013-03 Issue:3 Volume:143 Page:814-824
ISSN:0012-3692
Container-title:Chest
language:en
Short-container-title:Chest

Author:

Vij Rekha,Strek Mary E.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference77 articles.

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias

2. Cellular vs fibrosing interstitial pneumonias and prognosis: a practical classification of the idiopathic interstitial pneumonias and pathologically/radiologically similar conditions;Churg;Chest,2006

3. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society [published correction in Thorax. 2008;63(11):1029];Bradley;Thorax,2008

4. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies;Le Pavec;Arthritis Rheum,2011

5. Preliminary criteria for the classification of systemic sclerosis (scleroderma);Masi;Arthritis Rheum,1980

Cited by 260 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autoimmune Diseases;International Encyclopedia of Public Health;2025

2. Value of bronchoalveolar lavage fluid metagenomic next-generation sequencing in acute exacerbation of fibrosing interstitial lung disease: an individualized treatment protocol based on microbiological evidence;BMC Pulmonary Medicine;2024-08-20

3. Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review;Frontiers in Medicine;2024-08-06

4. Cancer and pulmonary fibrosis risks in patients with dermatomyositis and polymyositis: A retrospective cohort study;Heliyon;2024-07

5. Nintedanib combined with immunosuppressive agents improves forced vital capacity in connective tissue disease-associated PF-ILD: a single-center study;BMC Rheumatology;2024-06-18